IJH iShares Core S&P Mid-Cap ETF
- 58.710
- +1.230+2.14%
Peering Into EMCOR Group's Recent Short Interest
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
Baird Maintains Neutral on Illumina, Raises Price Target to $124
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
Inquiry Into Pure Storage's Competitor Dynamics In Technology Hardware, Storage & Peripherals Industry
Illumina Analyst Ratings
Williams-Sonoma Analyst Ratings
Illumina Non-GAAP EPS of $1.09 Beats by $0.19, Revenue of $1.09B In-line
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
BioMarin Pharmaceutical Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Evercore ISI Group Maintained an Outperform Rating on the Stock and Raised Its Price Target From $113 to $115.
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Illumina Q2 2024 Earnings Preview
Here's How Much $1000 Invested In Williams-Sonoma 20 Years Ago Would Be Worth Today
Here's How Much $100 Invested In Burlington Stores 10 Years Ago Would Be Worth Today
Looking Into Lennox Intl's Recent Short Interest
Best Volatility Ranking Stocks With Low Moves and Straddle Premiums Vs. History - BofA